RNXT has 36-month beta value of 1.08. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNXT is 34.89M, and currently, short sellers hold a 0.37% ratio of that float. The average trading volume of RNXT on February 21, 2025 was 145.93K shares.
RNXT) stock’s latest price update
RenovoRx Inc (NASDAQ: RNXT)’s stock price has gone decline by -8.04 in comparison to its previous close of 1.12, however, the company has experienced a -11.21% decrease in its stock price over the last five trading days. businesswire.com reported 2025-02-06 that MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. All shares in the offering are being sold by RenovoRx. The gross proceeds from the offering.
RNXT’s Market Performance
RenovoRx Inc (RNXT) has seen a -11.21% fall in stock performance for the week, with a -33.12% decline in the past month and a -5.50% plunge in the past quarter. The volatility ratio for the week is 9.88%, and the volatility levels for the past 30 days are at 8.17% for RNXT. The simple moving average for the past 20 days is -17.78% for RNXT’s stock, with a -12.71% simple moving average for the past 200 days.
RNXT Trading at -21.07% from the 50-Day Moving Average
After a stumble in the market that brought RNXT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.62% of loss for the given period.
Volatility was left at 8.17%, however, over the last 30 days, the volatility rate increased by 9.88%, as shares sank -30.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.36% lower at present.
During the last 5 trading sessions, RNXT fell by -11.21%, which changed the moving average for the period of 200-days by -18.90% in comparison to the 20-day moving average, which settled at $1.2527. In addition, RenovoRx Inc saw -20.16% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNXT
The total capital return value is set at -1.22. Equity return is now at value -258.95, with -135.25 for asset returns.
Currently, EBITDA for the company is -11.39 million with net debt to EBITDA at 1.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.39.
Conclusion
To put it simply, RenovoRx Inc (RNXT) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
